Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
72High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07425808CT.gov FLT3-ITD Targeted Therapy in Fit AML Patients | — | Not Yet Recruiting | — | — | — |
NCT07623187CT.gov A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy | — | Not Yet Recruiting | — | — | — |
NCT07645469CT.gov FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia | — | Not Yet Recruiting | — | — | — |
NCT07463768CT.gov Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy. | — | Not Yet Recruiting | — | — | — |
NCT07581002CT.gov A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) | — | Not Yet Recruiting | — | — | — |
NCT07605949CT.gov Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML | — | Not Yet Recruiting | — | — | — |
NCT05554419CT.gov Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) | — | Not Yet Recruiting | — | — | — |
NCT07439211CT.gov Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia | — | Not Yet Recruiting | — | — | — |
NCT07575412CT.gov SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS | — | Not Yet Recruiting | — | — | — |
NCT07642453CT.gov VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia. | — | Not Yet Recruiting | — | — | — |
Show 388 more trialsShow fewer
NCT07635485CT.gov VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML | — | Not Yet Recruiting | — | — | — |
NCT07562568CT.gov SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS | — | Not Yet Recruiting | — | — | — |
NCT07508982CT.gov Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML | — | Recruiting | — | — | — |
NCT07548983CT.gov Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation | — | Not Yet Recruiting | — | — | — |
NCT07490288CT.gov Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML | — | Recruiting | — | — | — |
NCT07583888CT.gov VABu Conditioning in Elderly AML HSCT | — | Recruiting | — | — | — |
NCT07548710CT.gov Study of SA+X in the Treatment of Newly Diagnosed AML | — | Recruiting | — | — | — |
NCT07471841CT.gov Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax | — | Not Yet Recruiting | — | — | — |
NCT07572695CT.gov Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML | — | Not Yet Recruiting | — | — | — |
NCT07407140CT.gov VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML | — | Not Yet Recruiting | — | — | — |
NCT07539818CT.gov Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML | — | Not Yet Recruiting | — | — | — |
NCT07514832CT.gov VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial | — | Recruiting | — | — | — |
NCT07469046CT.gov VAH vs VA in Newly Diagnosed Elderly AML | — | Not Yet Recruiting | — | — | — |
NCT07060001CT.gov Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker | — | Not Yet Recruiting | — | — | — |
NCT06782542CT.gov Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy | — | Recruiting | — | — | — |
NCT07507825CT.gov Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) | — | Not Yet Recruiting | — | — | — |
NCT07651475CT.gov Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | — | Active Not Recruiting | — | — | — |
NCT07177079CT.gov High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) | — | Recruiting | — | — | — |
NCT07486726CT.gov Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia | — | Not Yet Recruiting | — | — | — |
NCT07486479CT.gov Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | — | Not Yet Recruiting | — | — | — |
NCT07392814CT.gov Study With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia | — | Not Yet Recruiting | — | — | — |
NCT07255872CT.gov A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia | — | Not Yet Recruiting | — | — | — |
NCT07651176CT.gov Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | — | Enrolling By Invitation | — | — | — |
NCT07651163CT.gov Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | — | Enrolling By Invitation | — | — | — |
NCT06557421CT.gov De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients | — | Recruiting | — | — | — |
NCT07148180CT.gov A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax | — | Recruiting | — | — | — |
NCT07407660CT.gov Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax | — | Not Yet Recruiting | — | — | — |
NCT07425782CT.gov Venetoclax Combined With Azacitidine for Consolidation Therapy in AML | — | Not Yet Recruiting | — | — | — |
NCT07392242CT.gov A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT07259707CT.gov Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML | — | Recruiting | — | — | — |
NCT07303660CT.gov A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients | — | Not Yet Recruiting | — | — | — |
NCT07320235CT.gov Imetelstat Combinations in Relapsed AML | — | Recruiting | — | — | — |
NCT07304011CT.gov Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent | — | Recruiting | — | — | — |
NCT06770257CT.gov Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy | — | Withdrawn | — | — | — |
NCT07458542CT.gov Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT07236931CT.gov Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Naïve AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells | — | Not Yet Recruiting | — | — | — |
NCT06611839CT.gov Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML | — | Recruiting | — | — | — |
NCT07007312CT.gov Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | — | Recruiting | — | — | — |
NCT07172204CT.gov Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML | — | Recruiting | — | — | — |
NCT07132684CT.gov Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients | — | Recruiting | — | — | — |
NCT07108530CT.gov Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study | — | Recruiting | — | — | — |
NCT06763341CT.gov A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT07044687CT.gov Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India | — | Recruiting | — | — | — |
NCT07078591CT.gov Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML | — | Recruiting | — | — | — |
NCT07028086CT.gov VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma | — | Recruiting | — | — | — |
NCT06903702CT.gov A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06852222CT.gov A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Recruiting | — | — | — |
NCT07007949CT.gov a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06454409CT.gov Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Suspended | — | — | — |
NCT06572982CT.gov Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) Patients | — | Active Not Recruiting | — | — | — |
NCT06696183CT.gov Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment | — | Recruiting | — | — | — |
NCT05766514CT.gov Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction | — | Withdrawn | — | — | — |
NCT06737523CT.gov Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML | — | Recruiting | — | — | — |
NCT06548230CT.gov A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | — | Recruiting | — | — | — |
NCT06841952CT.gov Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia | — | Not Yet Recruiting | — | — | — |
NCT06445907CT.gov Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT06778187CT.gov Oral-ATO for TP53-mutated Myeloid Malignancies | — | Recruiting | — | — | — |
NCT06616636CT.gov A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) | — | Recruiting | — | — | — |
NCT06498973CT.gov Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant | — | Recruiting | — | — | — |
NCT06744556CT.gov HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML | — | Active Not Recruiting | — | — | — |
NCT06783790CT.gov Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT | — | Recruiting | — | — | — |
NCT06754540CT.gov Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention. | — | Not Yet Recruiting | — | — | — |
NCT06456463CT.gov A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy | — | Recruiting | — | — | — |
NCT06773208CT.gov A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML) | — | Recruiting | — | — | — |
NCT06504459CT.gov Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML | — | Recruiting | — | — | — |
NCT06810791CT.gov HVA vs IA/DA or VA in the Treatment of ND HR-AML | — | Recruiting | — | — | — |
NCT06664879CT.gov ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial | — | Active Not Recruiting | — | — | — |
NCT06746519CT.gov BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT05367401CT.gov A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants | — | Withdrawn | — | — | — |
NCT06656494CT.gov ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies | — | Recruiting | — | — | — |
NCT06514261CT.gov Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML | — | Suspended | — | — | — |
NCT06668558CT.gov Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06158100CT.gov Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) | — | Suspended | — | — | — |
NCT06511882CT.gov Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD | — | Recruiting | — | — | — |
NCT06370000CT.gov Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality | — | Recruiting | — | — | — |
NCT06741722CT.gov Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML | — | Recruiting | — | — | — |
NCT06497062CT.gov Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT05628623CT.gov Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment | — | Not Yet Recruiting | — | — | — |
NCT05823480CT.gov Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS | — | Withdrawn | — | — | — |
NCT07163793CT.gov Pilot Study of Reduced Venetoclax Exposure | — | Recruiting | — | — | — |
NCT06586099CT.gov Tislelizumab with Azacitidine in the Treatment of R/R AML | — | Withdrawn | — | — | — |
NCT06634394CT.gov APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | — | Recruiting | — | — | — |
NCT06635681CT.gov Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML | — | Recruiting | — | — | — |
NCT06317649CT.gov Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | — | Recruiting | — | — | — |
NCT05554406CT.gov Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | — | Recruiting | — | — | — |
NCT05554393CT.gov Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | — | Recruiting | — | — | — |
NCT06150040CT.gov Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] | — | Terminated | — | — | — |
NCT06357182CT.gov Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06451861CT.gov Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML | — | Recruiting | — | — | — |
NCT06508489CT.gov A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies | — | Terminated | — | — | — |
NCT06386302CT.gov Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT05720988CT.gov Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT06384261CT.gov A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy | — | Active Not Recruiting | — | — | — |
NCT06571825CT.gov RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR | — | Recruiting | — | — | — |
NCT06483906CT.gov Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML. | — | Recruiting | — | — | — |
NCT05564390CT.gov MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | — | Recruiting | — | — | — |
NCT06389292CT.gov A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06372717CT.gov A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS | — | Recruiting | — | — | — |
NCT06419634CT.gov Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Recruiting | — | — | — |
NCT07131059CT.gov MRD-positive AML Clinical Study | — | Recruiting | — | — | — |
NCT06326697CT.gov Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML) | — | Completed | — | — | — |
NCT05442216CT.gov Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents | — | Recruiting | — | — | — |
NCT06387420CT.gov A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia | — | Not Yet Recruiting | — | — | — |
NCT06387069CT.gov A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06177067CT.gov Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT05904106CT.gov Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML | — | Recruiting | — | — | — |
NCT06316960CT.gov Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation | — | Recruiting | — | — | — |
NCT06030089CT.gov Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven | — | Completed | — | — | — |
NCT06394011CT.gov Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients | — | Recruiting | — | — | — |
NCT06232655CT.gov Cladribine Venetoclax in Monocytic AML | — | Recruiting | — | — | — |
NCT06220162CT.gov VAC Regimen for AML Patients Who Failed to Response to VA Regimen | — | Recruiting | — | — | — |
NCT06345365CT.gov MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Recruiting | — | — | — |
NCT06014489CT.gov A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML | — | Recruiting | — | — | — |
NCT06022003CT.gov Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06429098CT.gov Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML | — | Recruiting | — | — | — |
NCT05883956CT.gov A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia | — | Active Not Recruiting | — | — | — |
NCT06073769CT.gov A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06180863CT.gov Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients | — | Withdrawn | — | — | — |
NCT06066905CT.gov A Study of Chidamide With AZA in MRD Positive AML After Transplant | — | Recruiting | — | — | — |
NCT05834244CT.gov A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) | — | Recruiting | — | — | — |
NCT06105658CT.gov Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML | — | Unknown | — | — | — |
NCT06008405CT.gov Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy | — | Unknown | — | — | — |
NCT06532058CT.gov Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT05955261CT.gov A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia | — | Suspended | — | — | — |
NCT05735184CT.gov A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | — | Recruiting | — | — | — |
NCT06256627CT.gov The Maintenance Treatment of "ITIVA" in AML Patients | — | Recruiting | — | — | — |
NCT05907057CT.gov An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. | — | Recruiting | — | — | — |
NCT06565975CT.gov Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France | — | Completed | — | — | — |
NCT05833438CT.gov Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy | — | Active Not Recruiting | — | — | — |
NCT05805072CT.gov Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients | — | Unknown | — | — | — |
NCT05736978CT.gov Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results | — | Recruiting | — | — | — |
NCT05772273CT.gov PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT | — | Recruiting | — | — | — |
NCT05586074CT.gov HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML | — | Recruiting | — | — | — |
NCT03932318CT.gov Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients | — | Withdrawn | — | — | — |
NCT05744440CT.gov Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCT | — | Unknown | — | — | — |
NCT05736965CT.gov A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT05641259CT.gov A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML | — | Unknown | — | — | — |
NCT05520567CT.gov A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT05246384CT.gov Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT05287568CT.gov CC-486 and Venetoclax for Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT05829226CT.gov A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) | — | Completed | — | — | — |
NCT05603884CT.gov VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Recruiting | — | — | — |
NCT05662956CT.gov A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients | — | Completed | — | — | — |
NCT05226455CT.gov Venetoclax in Patients With MDS or AML in Relapse After AHSCT | — | Active Not Recruiting | — | — | — |
NCT05788679CT.gov A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS | — | Recruiting | — | — | — |
NCT05476770CT.gov Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | — | Recruiting | — | — | — |
NCT05654194CT.gov Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML | — | Completed | — | — | — |
NCT05453903CT.gov A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies | — | Active Not Recruiting | — | — | — |
NCT05183035CT.gov Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | — | Recruiting | — | — | — |
NCT05401097CT.gov IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) | — | Recruiting | — | — | — |
NCT05471700CT.gov Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients | — | Completed | — | — | — |
NCT05413018CT.gov An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission | — | Active Not Recruiting | — | — | — |
NCT05079230CT.gov Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT06827899CT.gov Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML | — | Recruiting | — | — | — |
NCT05361057CT.gov Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients | — | Terminated | — | — | — |
NCT05404906CT.gov AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission | — | Recruiting | — | — | — |
NCT05428969CT.gov A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies | — | Active Not Recruiting | — | — | — |
NCT05155709CT.gov A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. | — | Completed | — | — | — |
NCT05433532CT.gov Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients | — | Completed | — | — | — |
NCT05107856CT.gov PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | — | Terminated | — | — | — |
NCT05275439CT.gov Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML | — | Terminated | — | — | — |
NCT04867928CT.gov Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT05457361CT.gov VAH Versus VA for Salvage Therapy of R/R-AML | — | Unknown | — | — | — |
NCT04988555CT.gov A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | — | Recruiting | — | — | — |
NCT04905810CT.gov Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure | — | Recruiting | — | — | — |
NCT05270200CT.gov Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse | — | Recruiting | — | — | — |
NCT05823714CT.gov Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT | — | Unknown | — | — | — |
NCT05168202CT.gov A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes | — | Terminated | — | — | — |
NCT05197426CT.gov A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission | — | Active Not Recruiting | — | — | — |
NCT04937166CT.gov A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies | — | Terminated | — | — | — |
NCT05305859CT.gov Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML | — | Recruiting | — | — | — |
NCT05144243CT.gov Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China | — | Active Not Recruiting | — | — | — |
NCT05140811CT.gov A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | — | Unknown | — | — | — |
NCT04887857CT.gov A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT05042531CT.gov Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT05053425CT.gov Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML | — | Unknown | — | — | — |
NCT04623216CT.gov Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. | — | Terminated | — | — | — |
NCT04905407CT.gov Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
NCT04980885CT.gov A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT05048615CT.gov Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML | — | Completed | — | — | — |
NCT04964505CT.gov Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT04778397CT.gov Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated | — | Terminated | — | — | — |
NCT04912063CT.gov Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome | — | Terminated | — | — | — |
NCT04771130CT.gov A Study of BGB-11417 in Participants With Myeloid Malignancies | — | Recruiting | — | — | — |
NCT04801797CT.gov Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | — | Active Not Recruiting | — | — | — |
NCT04842604CT.gov Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML | — | Completed | — | — | — |
NCT04755244CT.gov A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) | — | Terminated | — | — | — |
NCT04913922CT.gov Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML | — | Unknown | — | — | — |
NCT05175508CT.gov Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS | — | Unknown | — | — | — |
NCT05048498CT.gov Pharmacokinetics, Tolerability and Safety of NEX-18a | — | Completed | — | — | — |
NCT04730258CT.gov A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML | — | Active Not Recruiting | — | — | — |
NCT04752163CT.gov DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT04742101CT.gov Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT04824924CT.gov A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy | — | Unknown | — | — | — |
NCT05264883CT.gov Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML | — | Unknown | — | — | — |
NCT04629443CT.gov Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia | — | Completed | — | — | — |
NCT04284787CT.gov BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT04229979CT.gov Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 | — | Active Not Recruiting | — | — | — |
NCT04712942CT.gov Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat | — | Completed | — | — | — |
NCT04904237CT.gov Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML. | — | Unknown | — | — | — |
NCT04358393CT.gov A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | — | Unknown | — | — | — |
NCT04599452CT.gov NK Cell Therapy Recurrent/Refractory Elderly AML | — | Unknown | — | — | — |
NCT04609826CT.gov A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | — | Completed | — | — | — |
NCT04603001CT.gov Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | — | Active Not Recruiting | — | — | — |
NCT04518345CT.gov TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT04687761CT.gov Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old | — | Completed | — | — | — |
NCT04581512CT.gov Study to Evaluate the Safety and Tolerability of EP0042 | — | Recruiting | — | — | — |
NCT06379360CT.gov Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients | — | Recruiting | — | — | — |
NCT04230564CT.gov Acute Myeloid Leukemia Real World Treatment Patterns | — | Withdrawn | — | — | — |
NCT04146038CT.gov Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | — | Completed | — | — | — |
NCT04266795CT.gov A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy | — | Completed | — | — | — |
NCT04501120CT.gov Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML | — | Recruiting | — | — | — |
NCT04485052CT.gov Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia | — | Suspended | — | — | — |
NCT04553692CT.gov Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | — | Terminated | — | — | — |
NCT04490707CT.gov Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML | — | Unknown | — | — | — |
NCT04150029CT.gov A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy | — | Terminated | — | — | — |
NCT04227847CT.gov A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | — | Recruiting | — | — | — |
NCT04336982CT.gov A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT04435691CT.gov Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT04487106CT.gov Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT04275518CT.gov A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. | — | Recruiting | — | — | — |
NCT04424147CT.gov Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML | — | Completed | — | — | — |
NCT04256317CT.gov A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | — | Recruiting | — | — | — |
NCT04128501CT.gov Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | — | Active Not Recruiting | — | — | — |
NCT04102020CT.gov A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy | — | Completed | — | — | — |
NCT04241549CT.gov A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment | — | Completed | — | — | — |
NCT03701295CT.gov Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement | — | Completed | — | — | — |
NCT04161885CT.gov A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
NCT03765541CT.gov Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT04172844CT.gov Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia | — | Terminated | — | — | — |
NCT04243785CT.gov A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | — | Recruiting | — | — | — |
NCT04296214CT.gov Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT04150887CT.gov Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT04140487CT.gov Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm | — | Recruiting | — | — | — |
NCT04248595CT.gov Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML | — | Unknown | — | — | — |
NCT03926624CT.gov Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage | — | Terminated | — | — | — |
NCT04086264CT.gov IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT06550713CT.gov A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies | — | Recruiting | — | — | — |
NCT04128020CT.gov Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia | — | Withdrawn | — | — | — |
NCT04090736CT.gov Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT04062266CT.gov AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission | — | Active Not Recruiting | — | — | — |
NCT04022785CT.gov PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT03769532CT.gov MRD-guided Treatment in NPM1mut AML Patients | — | Terminated | — | — | — |
NCT04061239CT.gov Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML | — | Recruiting | — | — | — |
NCT03874052CT.gov Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT03941964CT.gov A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | — | Completed | — | — | — |
NCT04068597CT.gov Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | — | Recruiting | — | — | — |
NCT04023526CT.gov A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT03814005CT.gov A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems | — | Completed | — | — | — |
NCT04173533CT.gov Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT | — | Unknown | — | — | — |
NCT03745352CT.gov Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT03813147CT.gov Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT03843528CT.gov Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation | — | Active Not Recruiting | — | — | — |
NCT03850574CT.gov Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT03862157CT.gov Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT05456048CT.gov Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML | — | Completed | — | — | — |
NCT03612739CT.gov EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 | — | Withdrawn | — | — | — |
NCT03573024CT.gov Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03513484CT.gov Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03586609CT.gov Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT03613532CT.gov Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN | — | Active Not Recruiting | — | — | — |
NCT03483948CT.gov Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT03699384CT.gov Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) | — | Withdrawn | — | — | — |
NCT03683433CT.gov Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | — | Recruiting | — | — | — |
NCT03588078CT.gov Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine | — | Unknown | — | — | — |
NCT03465540CT.gov Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | — | Terminated | — | — | — |
NCT03709576CT.gov Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML | — | Terminated | — | — | — |
NCT03493646CT.gov Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 | — | Completed | — | — | — |
NCT03466294CT.gov Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML | — | Completed | — | — | — |
NCT03530683CT.gov A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma | — | Terminated | — | — | — |
NCT03416179CT.gov A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03338348CT.gov Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 | — | Completed | — | — | — |
NCT03471260CT.gov Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | — | Recruiting | — | — | — |
NCT03397173CT.gov TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid | — | Completed | — | — | — |
NCT03092674CT.gov Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT03383575CT.gov Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | — | Recruiting | — | — | — |
NCT03390296CT.gov OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03268954CT.gov Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) | — | Completed | — | — | — |
NCT03298516CT.gov A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy | — | Completed | — | — | — |
NCT03217838CT.gov Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. | — | Terminated | — | — | — |
NCT03194932CT.gov Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage | — | Completed | — | — | — |
NCT03066648CT.gov Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | — | Completed | — | — | — |
NCT03113643CT.gov SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | — | Recruiting | — | — | — |
NCT03173248CT.gov Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation | — | Active Not Recruiting | — | — | — |
NCT03151408CT.gov An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT03164057CT.gov A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03072043CT.gov Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | — | Completed | — | — | — |
NCT03146871CT.gov Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent | — | Terminated | — | — | — |
NCT02942758CT.gov Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML | — | Terminated | — | — | — |
NCT02995655CT.gov CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02953561CT.gov Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02993523CT.gov A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy | — | Active Not Recruiting | — | — | — |
NCT03030612CT.gov A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) | — | Completed | — | — | — |
NCT02954653CT.gov A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT03013998CT.gov Study of Biomarker-Based Treatment of Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT02807558CT.gov A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT02752035CT.gov A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy | — | Completed | — | — | — |
NCT02750254CT.gov Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | — | Terminated | — | — | — |
NCT02675452CT.gov AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02677922CT.gov A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT02775903CT.gov An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT02782468CT.gov A Study of Pevonedistat in Adult East Asian Participants | — | Completed | — | — | — |
NCT02785900CT.gov Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02719574CT.gov Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | — | Completed | — | — | — |
NCT02610777CT.gov An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | — | Completed | — | — | — |
NCT02750995CT.gov Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML | — | Completed | — | — | — |
NCT02421939CT.gov A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | — | Completed | — | — | — |
NCT02543879CT.gov Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | — | Completed | — | — | — |
NCT02450877CT.gov A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia. | — | Completed | — | — | — |
NCT02343939CT.gov Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
NCT02458235CT.gov Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation | — | Completed | — | — | — |
NCT02472691CT.gov Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT | — | Completed | — | — | — |
NCT02367456CT.gov A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients | — | Completed | — | — | — |
NCT02399917CT.gov Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02397720CT.gov Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02348489CT.gov SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction | — | Completed | — | — | — |
NCT02351037CT.gov Study of Ibrutinib in Subjects With Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02303782CT.gov A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT) | — | Withdrawn | — | — | — |
NCT03284593CT.gov Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition | — | Active Not Recruiting | — | — | — |
NCT02319369CT.gov Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | — | Terminated | — | — | — |
NCT02223052CT.gov Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | — | Completed | — | — | — |
NCT02203773CT.gov Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) | — | Terminated | — | — | — |
NCT02129101CT.gov Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | — | Completed | — | — | — |
NCT02038777CT.gov A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies | — | Completed | — | — | — |
NCT02071927CT.gov Study of the Glutaminase Inhibitor CB-839 in Leukemia | — | Completed | — | — | — |
NCT01912274CT.gov Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT01588951CT.gov Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior | — | Terminated | — | — | — |
NCT01995578CT.gov Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse | — | Completed | — | — | — |
NCT01892371CT.gov Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT01835587CT.gov Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). | — | Completed | — | — | — |
NCT01369368CT.gov Treatment of Acute Leukemia Relapse After Allotransplantation | — | Unknown | — | — | — |
NCT01926587CT.gov Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine | — | Completed | — | — | — |
NCT01869114CT.gov Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy | — | Completed | — | — | — |
NCT01908387CT.gov Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | — | Terminated | — | — | — |
NCT01700673CT.gov Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS | — | Completed | — | — | — |
NCT01757535CT.gov Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission | — | Completed | — | — | — |
NCT01747499CT.gov Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation | — | Terminated | — | — | — |
NCT01814826CT.gov Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older | — | Completed | — | — | — |
NCT01794169CT.gov Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML | — | Terminated | — | — | — |
NCT02341495CT.gov Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65 | — | Terminated | — | — | — |
NCT01743859CT.gov Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01636609CT.gov Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | — | Terminated | — | — | — |
NCT01617226CT.gov Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS | — | Completed | — | — | — |
NCT01839240CT.gov Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01358734CT.gov A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01390311CT.gov Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant | — | Completed | — | — | — |
NCT01556477CT.gov The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q). | — | Unknown | — | — | — |
NCT01519011CT.gov Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine | — | Completed | — | — | — |
NCT02124174CT.gov Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS | — | Unknown | — | — | — |
NCT01541280CT.gov VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT01462578CT.gov Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza) | — | Completed | — | — | — |
NCT01442714CT.gov Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS | — | Terminated | — | — | — |
NCT01305499CT.gov A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) | — | Unknown | — | — | — |
NCT01249430CT.gov Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01301820CT.gov Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR) | — | Completed | — | — | — |
NCT01488565CT.gov A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia | — | Completed | — | — | — |
NCT01260714CT.gov Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT05188326CT.gov Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients | — | Completed | — | — | — |
NCT01180322CT.gov Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine | — | Completed | — | — | — |
NCT01168219CT.gov Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01074047CT.gov Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT01067274CT.gov ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML) | — | Withdrawn | — | — | — |
NCT01110473CT.gov ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies | — | Completed | — | — | — |
NCT01083706CT.gov Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant | — | Completed | — | — | — |
NCT01016600CT.gov Azacitidine and Lenalidomide for Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00636922CT.gov Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT00915252CT.gov Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT00923234CT.gov Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes | — | Terminated | — | — | — |
NCT00911066CT.gov MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00895934CT.gov Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML | — | Completed | — | — | — |
NCT00887068CT.gov Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) | — | Completed | — | — | — |
NCT00890929CT.gov Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT00658814CT.gov Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT00652626CT.gov Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function | — | Completed | — | — | — |
NCT00795548CT.gov Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation | — | Completed | — | — | — |
NCT00761722CT.gov Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma | — | Completed | — | — | — |
NCT00728520CT.gov Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy | — | Unknown | — | — | — |
NCT00666497CT.gov Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | — | Terminated | — | — | — |
NCT00528983CT.gov Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia | — | Completed | — | — | — |
NCT00392353CT.gov Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT00313586CT.gov Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00446303CT.gov A Phase II Study of Maintenance With Azacitidine in MDS Patients | — | Terminated | — | — | — |
NCT00351975CT.gov Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases | — | Completed | — | — | — |
NCT00569010CT.gov Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) | — | Completed | — | — | — |
NCT00326170CT.gov Phase II 5-Azacytidine Plus VPA Plus ATRA | — | Completed | — | — | — |
NCT00766116CT.gov Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT00101179CT.gov MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03723135CT.gov Expanded Access for CC-486 | — | Approved For Marketing | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Azacitidine (this asset) | European Organisation for Research and Treatment of Cancer - EORTC | Approved | BB · 69 |
| Gemtuzumab | M.D. Anderson Cancer Center | P4 | A |
| Amsacrine | University Hospital, Toulouse | P4 | BBB |
| Posaconazole | AstraZeneca | P4 | BBB |
| (+)-Vincristine | Janssen Research & Development, LLC | P3 | BBB |
| Aclacinomycin | Chinese PLA General Hospital | P4 | BB |
| Alvocidib | M.D. Anderson Cancer Center | P2 | BB |
| Prednisone | Children's Oncology Group | P3 | BB |
| Therapeutic Allogeneic Lymphocytes | University of Southern California | P2 | BB |
+42 more in the Acute Myeloid Leukemia cohort
Other indications for Azacitidine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 73 |
| Acute Erythroid Leukemia | — | P2 | BB · 71 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Azacitidine in Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/azacitidine-acute-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →